Bristol-Myers Squibb (BMY) To Go Ex-Dividend on July 5th

Bristol-Myers Squibb (NYSE:BMY) declared a quarterly dividend on Tuesday, June 18th, RTT News reports. Shareholders of record on Friday, July 5th will be given a dividend of 0.60 per share by the biopharmaceutical company on Thursday, August 1st. This represents a $2.40 dividend on an annualized basis and a yield of 5.88%. The ex-dividend date of this dividend is Friday, July 5th.

Bristol-Myers Squibb has decreased its dividend by an average of 0.2% per year over the last three years and has increased its dividend every year for the last 16 years. Bristol-Myers Squibb has a dividend payout ratio of 34.6% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Bristol-Myers Squibb to earn $7.05 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 34.0%.

Bristol-Myers Squibb Trading Down 0.4 %

Bristol-Myers Squibb stock opened at $40.81 on Thursday. The business has a 50-day simple moving average of $43.89 and a two-hundred day simple moving average of $48.55. Bristol-Myers Squibb has a 52-week low of $39.91 and a 52-week high of $66.38. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The company has a market cap of $82.73 billion, a P/E ratio of -13.16, a P/E/G ratio of 13.87 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. During the same period in the previous year, the business posted $2.05 earnings per share. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. Analysts predict that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on BMY shares. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. BMO Capital Markets decreased their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th. Barclays cut their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Wells Fargo & Company increased their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Finally, Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.